Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This non-controlled multicentre phase II study is designed to assess the safety and to
describe (in relation to children of higher age) the pharmacodynamics of recombinant ASNase
(rASNase) for first-line treatment of infants (< 1 year of age at diagnosis) with de novo
acute lymphoblastic leukaemia